Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16214300 | 1.00 | THRB (0.34) | THRB | |
| SCHEMBL21733117 | 0.86 | HSD17B10 (0.35) | — | |
| SCHEMBL31380117 | 0.86 | HSD17B10 (0.35) | — | |
| SCHEMBL10215089 | 0.84 | LMNA (0.40) | THRB | |
| SCHEMBL22994948 | 0.79 | LMNA (0.35) | THRB | |
| SCHEMBL77068 | 0.78 | NPC1 (0.36) | THRB | |
| SCHEMBL383965 | 0.77 | — | — | |
| SCHEMBL25868489 | 0.77 | — | — | |
| SCHEMBL6284087 | 0.76 | TSHR (0.48) | THRB | |
| SCHEMBL14963645 | 0.75 | LMNA (0.46) | THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9217041-B2 | Antibodies that inhibit metalloproteins | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2015-12-22 | — | — | US | disclosed |
| US-20140141014-A1 | ANTIBODIES THAT INHIBIT METALLOPROTEINS | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2014-05-22 | — | — | US | disclosed |
| US-8697078-B2 | Antibodies that inhibit metalloproteins | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2014-04-15 | — | — | US | disclosed |
| US-20130209491-A1 | METHODS OF GENERATING ANTIBODIES TO METALLOENZYMES | YEDA RESEARCH AND DEVELOPMENT CO., LTD. (IL) | 2013-08-15 | — | — | US | disclosed |
| US-20130039922-A1 | ANTIBODIES THAT INHIBIT METALLOPROTEINS | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2013-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130209491-A1 | METHODS OF GENERATING ANTIBODIES TO METALLOENZYMES | ME1, SOD1, MPO | THRB 3946/4885 |
| US-20140141014-A1 | ANTIBODIES THAT INHIBIT METALLOPROTEINS | NOS2, NOS3, NOS1 | THRB 2957/4885 |
| US-20130039922-A1 | ANTIBODIES THAT INHIBIT METALLOPROTEINS | MMP12, MMP1, MMP8 | THRB 3427/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.